LSD clinical trials in the registry
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
LSD (lysergic acid diethylamide) is a semi-synthetic compound first made from a substance found in ergot fungus. This page summarises registered studies whose registry records mention LSD, using PsychoactiveMap's copy of the ClinicalTrials.gov registry.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 49 registered LSD studies are counted on this page.
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 10 | 20% |
| Not yet recruiting | 2 | 4% |
| Active, not recruiting | 6 | 12% |
| Completed | 29 | 59% |
| Terminated | 1 | 2% |
| Status not reported | 1 | 2% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 7 | 14% |
| Phase 1 | 20 | 41% |
| Phase 2 | 10 | 20% |
| Phase 3 | 3 | 6% |
| Not applicable | 6 | 12% |
| Not reported | 3 | 6% |
Countries
Country is taken from the study's linked research site. 0 of 49 records have no country on file. The top 6 countries are shown.
| Country | Studies | Share |
|---|---|---|
| Switzerland | 31 | 63% |
| United States | 11 | 22% |
| Netherlands | 4 | 8% |
| Canada | 1 | 2% |
| Denmark | 1 | 2% |
| United Kingdom | 1 | 2% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 24 |
| 2020 to 2023 | 14 |
| 2015 to 2019 | 8 |
| 2010 to 2014 | 2 |
| Before 2010 | 1 |
Study design
- 46 interventional and 3 observational studies.
- Median planned or actual enrolment is 30 participants (range 10 to 376, across 49 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Healthy volunteers | 12 |
| Depression and mood | 6 |
| Anxiety | 5 |
| Pain and headache | 4 |
| Trauma and PTSD | 1 |
| Alcohol use | 1 |
| Cancer and end of life | 1 |
Most recently started studies
The 25 studies with the latest start dates, shown newest first. The order is not a ranking and says nothing about quality. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07503002 | Shortened LSD Intervention for Major Depressive Disorder | Not yet recruiting | Phase 1 | United States | 2026-07 |
| NCT07053917 | Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability | Recruiting | Phase 1 | United States | 2026-02 |
| NCT07309471 | Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD | Recruiting | Not applicable | Switzerland | 2026-01 |
| NCT07189299 | Microdosing LSD in Women With Premenstrual Disorders | Not yet recruiting | Not applicable | Switzerland | 2025-10 |
| NCT06927076 | Antidepressant Response of DMT Masked With Propofol | Recruiting | Not applicable | Switzerland | 2025-08 |
| NCT07061886 | Drug Effects on Mood and Behavior - Expectancy | Completed | Early Phase 1 | United States | 2025-06 |
| NCT07017478 | Mood Effects of Serotonin Agonists: Depression | Completed | Early Phase 1 | United States | 2025-06 |
| NCT05477459 | LSD to Improve Cluster Headache Impact Trial | Recruiting | Phase 2 | Netherlands | 2025-04 |
| NCT06941844 | A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | Active, not recruiting | Phase 3 | United States | 2025-04 |
| NCT06884514 | Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects | Completed | Phase 1 | Switzerland | 2025-04 |
| NCT06899334 | Direct Comparison of Altered States of Consciousness Induced by LSD, Psilocybin, and DMT in Healthy Participants | Recruiting | Phase 1 | Switzerland | 2025-04 |
| NCT06809595 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | Active, not recruiting | Phase 3 | United States | 2025-01 |
| NCT06180759 | Acute Analgesic Effects of DMT on Experimentally Induced Pain in Healthy Participants | Completed | Phase 1 | Switzerland | 2025-01 |
| NCT06624137 | Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics | Terminated | Not reported | United States | 2024-12 |
| NCT06741228 | A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | Active, not recruiting | Phase 3 | United States | 2024-12 |
| NCT06506019 | Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression | Active, not recruiting | Phase 1 | Canada | 2024-10 |
| NCT06557239 | Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy | Completed | Not reported | Switzerland | 2024-08 |
| NCT05883540 | Lysergic Acid Diethylamide (LSD) in Palliative Care | Recruiting | Phase 2 | Switzerland | 2024-06 |
| NCT05474989 | LSD Treatment for Persons With Alcohol Use Disorder | Recruiting | Phase 2 | Switzerland | 2024-06 |
| NCT06368492 | The Impact of Psilocybin on Pain in Fibromyalgia Patients | Recruiting | Not applicable | Netherlands | 2024-05 |
| NCT05219175 | MDMA for Co-occurring PTSD and OUD After Childbirth | Recruiting | Phase 2 | United States | 2024-04 |
| NCT05976698 | LSD-Perceptual-Choice-Study | Completed | Not applicable | Switzerland | 2024-02 |
| NCT05964647 | Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects | Completed | Phase 1 | Switzerland | 2024-02 |
| NCT06252506 | Molecular Imaging Study of Harmine/DMT: a Basic Research Approach | Completed | Phase 1 | Switzerland | 2024-01 |
| NCT05953038 | LSD Occupancy of the Serotonin 2A Receptor in the Human Brain | Active, not recruiting | Early Phase 1 | Denmark | 2023-11 |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals.
Other substance hubs
Psilocybin | MDMA | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Phase not applicable